Bladder cancer, like many other cancers, can develop not only from environmental factors (such as smoking or exposure to chemicals), but also from genetic alterations that occur within bladder cells.
These mutations are not always hereditary, but they can appear spontaneously during our lifetime, without us noticing, and they affect how the tumor behaves: how aggressive it is, how it grows, and how it responds to treatments. Here are some of the most relevant mutations that research has identified:
FGFR3
- This is one of the most common mutations, especially in superficial, i.e., less aggressive, bladder cancers.
Those with this mutation often have disease that grows slowly and can be controlled more easily, although it tends to recur. Today there are also "smart" drugs that target precisely the cells with this mutation, paving the way for personalized therapies.
TP53 and RB1
- These genes are the "guardians" of DNA: they serve to repair damage in cells and stop abnormal growth.
When altered, cancer cells become more aggressive. These mutations are often found in muscle-invasive tumors, that is, those that grow deep in the bladder wall and require more intensive treatments (such as surgery or chemotherapy).
KDM6A
- This mutation is more common in women.
Researchers think it may explain, at least in part, some of the differences between men and women in the occurrence and evolution of bladder cancer. It's an area still under study, but it opens up important thoughts about "gender" medicine. If you are interested in learning more about how gender impacts bladder cancer incidence, sensitivity to treatment, and survival rates, we discussed this in our article "Men vs. women: differences in bladder cancer."
These mutations are not always hereditary, but they can appear spontaneously during our lifetime, without us noticing, and they affect how the tumor behaves: how aggressive it is, how it grows, and how it responds to treatments. Here are some of the most relevant mutations that research has identified:
FGFR3
- This is one of the most common mutations, especially in superficial, i.e., less aggressive, bladder cancers.
Those with this mutation often have disease that grows slowly and can be controlled more easily, although it tends to recur. Today there are also "smart" drugs that target precisely the cells with this mutation, paving the way for personalized therapies.
TP53 and RB1
- These genes are the "guardians" of DNA: they serve to repair damage in cells and stop abnormal growth.
When altered, cancer cells become more aggressive. These mutations are often found in muscle-invasive tumors, that is, those that grow deep in the bladder wall and require more intensive treatments (such as surgery or chemotherapy).
KDM6A
- This mutation is more common in women.
Researchers think it may explain, at least in part, some of the differences between men and women in the occurrence and evolution of bladder cancer. It's an area still under study, but it opens up important thoughts about "gender" medicine. If you are interested in learning more about how gender impacts bladder cancer incidence, sensitivity to treatment, and survival rates, we discussed this in our article "Men vs. women: differences in bladder cancer."
Why is it important to know about these mutations?
Knowing whether a tumor has one of these mutations helps doctors better understand the type of tumor and choose the most appropriate therapy: In the future, more and more bladder cancer patients will be able to receive "tailored" treatments designed around the genetic profile of their tumor. This is an important change, making medicine more precise, effective and often with fewer side effects.
From genetics to early diagnosis: the role of Urine24 in bladder cancer
Today we know that bladder cancer can be linked to specific genetic mutations that make some people more predisposed, or that make the tumor more aggressive. But genetics alone is not enough: what can really make a difference is discovering the tumor as early as possible.
That's where Urine24 comes in, an innovative test that performs a cytological examination of urine thoroughly and quickly and can detect early signs of cancer even before obvious symptoms appear.
That's where Urine24 comes in, an innovative test that performs a cytological examination of urine thoroughly and quickly and can detect early signs of cancer even before obvious symptoms appear.
Conclusion
If a person has a family history of bladder cancer, carries an inherited genetic mutation, or has been exposed to carcinogens at work, having regular checkups with Urine24 can make a difference. Discovering cancer at an early stage significantly increases the chances of cure, allows for less invasive interventions, and can prevent progression to more dangerous forms.
